Boundless Bio to Participate at Two Upcoming Investor Conferences

boundless-bio-to-participate-at-two-upcoming-investor-conferences

SAN DIEGO–(BUSINESS WIRE)–Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will participate in a presentation and fireside chat at upcoming investor conferences:

Piper Sandler 34th Annual Healthcare Conference

Format: Presentation

Date: Tuesday, November 29, 2022

Time: 8:30 AM – 8:50 AM ET

5th Annual Evercore ISI HealthCONx Conference

Format: Fireside chat (virtual)

Date: Tuesday, November 29, 2022

Time: 1:50 PM – 2:10 PM ET

About Boundless Bio

Boundless Bio is a next-generation precision oncology company dedicated to the discovery and development of a new class of drugs targeting a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Contacts

James Lee

Director of Business Development

Boundless Bio

[email protected]

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

For the last half century, thousands of communications professionals have turned to us to deliver their news to the audiences most important to their business through the sources they trust most. Over that time, we've gone from a single office with one full time employee to more than 500 employees in 32 bureaus.